In 179 US adults with obesity or overweight without type 2 diabetes, weekly mazdutide cut bodyweight at 32 weeks by 7·3% (3–6 mg), 15·6% (10 mg) and 18·1% (16 mg) vs 0·9% with placebo; GI effects common, 20% stopped 16 mg for adverse events.
RCTn = 179
Hsia et al. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial